- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021
GAITHERSBURG, Md., April 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2021 financial results and operational highlights on Monday, May 10, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details: | ||
Date: | May 10, 2021 | |
Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
Dial-in number: | (866) 652-5200 (Domestic) or (412) 317-6060 (International) | |
Webcast: | ||
• Participants will be prompted to request to join the Novavax, Inc. call. | ||
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast. | ||
Replay details: | |
Date: | Available starting at 7:30 p.m. ET, May 10, 2021 |
Dial-in number: | (877) 344-7529 (Domestic) or (412) 317-0088 (International) |
Passcode: | 10155684 |
Webcast: | www.novavax.com/events, until August 10, 2021 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
[email protected]
Solebury Trout
Jennifer Porcelli | 646-378-2962
[email protected]
Media
Amy Speak | 617-420-2461
Laura Keenan | 410-419-5755
[email protected]
SOURCE Novavax, Inc.
